Mianserin Orifarm (Mianserin Hydrochloride)

Mianserin works by blocking presynaptic α2‑adrenergic receptors and several serotonin receptors (such as 5‑HT2 and 5‑HT3). This blockade increases the release of norepinephrine and serotonin, enhancing neurotransmission that is often deficient in depression.

The appropriate dose of Mianserin Orifarm is determined by the prescribing clinician based on the patient’s condition, response, and tolerability. Dosage may be adjusted over time, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

Safety data for mianserin in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mianserin belongs to the tetracyclic class, differing from selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs) in its receptor‑blocking profile. It may cause more sedation and weight gain but can be useful when patients do not respond to or tolerate SSRIs.

Mianserin Orifarm should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat and direct sunlight to maintain stability and potency.

Mianserin Orifarm is taken orally, usually once daily in the evening with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include agranulocytosis, severe hypotension, cardiac arrhythmias, seizures, and the emergence or worsening of suicidal thoughts, especially at the start of therapy. Patients should be monitored closely for any signs of these conditions.

Mianserin is contraindicated in patients who have taken monoamine oxidase inhibitors within the past 14 days, those with known hypersensitivity to the drug, and individuals with severe liver impairment or uncontrolled cardiovascular disease. A healthcare professional should evaluate suitability before prescribing.